Collaborating in more than 150 markets. By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com. These sections or websites are governed by their own Legal and Privacy Policies.
Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
